SCHEMBL6281643

SCHEMBL6281643

CC(=O)Oc1ccc(C(=O)c2ccccc2)cc1C(C)C(=O)NS(C)(=O)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 5/20 0.55
PTGS2 P35354 5/20 0.55
ELANE P08246 5/20 0.54
CXCL8 P10145 2/20 0.42
HPGD P15428 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CXCR1 P25024 2/20 0.40
CXCR2 P25025 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3146376 0.82 PTGS1 (0.79) PTGS1PTGS2ELANECXCL8HPGD
SCHEMBL3146024 0.82 PTGS1 (0.79) PTGS1PTGS2ELANECXCL8HPGD
SCHEMBL1883565 0.77 MAPT (0.64) PTGS1PTGS2CXCL8HPGDCYP1A2
SCHEMBL1883564 0.77 MAPT (0.64) PTGS1PTGS2CXCL8HPGDCYP1A2
SCHEMBL11103539 0.75 PTGS2 (0.71) PTGS1PTGS2ELANECXCL8HPGD
SCHEMBL11103544 0.75 PTGS2 (0.71) PTGS1PTGS2ELANECXCL8HPGD
SCHEMBL11249840 0.73 TSHR (0.54) PTGS1PTGS2ELANEHPGDCYP1A2
SCHEMBL11102940 0.73 PTGS2 (0.64) PTGS1PTGS2ELANECXCL8HPGD
SCHEMBL11102943 0.73 PTGS2 (0.64) PTGS1PTGS2ELANECXCL8HPGD
SCHEMBL28887097 0.73 ALDH1A1 (0.71) PTGS1PTGS2ELANEHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed
EP-1123276-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Dompe' S.P.A. (IT) 2001-08-16 EP disclosed
WO-2000024710-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 PTGS1 29/4885PTGS2 48/4885ELANE 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.